Zoetis Inc(ZTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:57 PM ET (Korea 10/31 08:57)
Full metrics table
| Index | S&P 500 | P/E | 13.11 | EPS (ttm) | 6.08 | Insider Own | 0.23% | Shs Outstand | 414.1M | Perf Week | -1.62% |
| Market Cap | 32.94B | Forward P/E | 12.58 | EPS next Y | 1.97% | Insider Trans | 1.24% | Shs Float | 412.3M | Perf Month | 15.37% |
| Enterprise Value | 40.50B | PEG | 6.95 | EPS next Q | 1.51 | Inst Own | 100.39% | Short Float | 4.25% | Perf Quarter | 3.4% |
| Income | 2.62B | P/S | 3.46 | EPS this Y | -3.06% | Inst Trans | -3.95% | Short Ratio | 3.51 | Perf Half Y | -30.17% |
| Sales | 9.52B | P/B | 10.49 | EPS next 5Y | 1.81% | ROA | 17.7% | Short Interest | 17.52M | Perf YTD | -36.64% |
| Book/sh | 7.6 | P/C | 19.66 | EPS past 3/5Y | 10.25% 11.96% | ROE | 64.39% | 52W High | -45.04% ($145.04) | Perf Year | -44.68% |
| Cash/sh | 4.06 | P/FCF | 13.92 | Sales past 3/5Y | 5.42% 7.24% | ROIC | 21.12% | 52W Low | 15.92% ($68.77) | Perf 3Y | -49.22% |
| Dividend Est. | $2.11 (2.64%) | EV/EBITDA | 9.96 | EPS Y/Y TTM | 4.54% | Gross Margin | 70.22% | Volatility(W/M) | 2.06% 2.29% | Perf 5Y | -63.13% |
| Dividend TTM | 2.12 | EV/Sales | 4.26 | Sales Y/Y TTM | 1.41% | Oper. Margin | 37.65% | ATR (14) | 1.85 | Perf 10Y | 64.17% |
| Dividend Ex-Date | 2026/10/30 | Quick Ratio | 1.84 | EPS Q/Q | 2.64% | Profit Margin | 27.49% | RSI (14) | 60.44 | Recom | 2.5 |
| Dividend Gr. 3/5Y | 14.57% 19.02% | Current Ratio | 3.08 | Sales Q/Q | 0.33% | SMA20 | 3.33% ($77.15) | Beta | 0.7 | Target Price | $88 |
| Payout | 33.71% | Debt/Eq | 2.93 | Earnings | 2026/11/5 | SMA50 | 6.23% ($75.04) | Rel Volume | 0.82 | Prev Close | $78.8 |
| Employees | 14500 | LT Debt/Eq | 2.93 | EPS/Sales Surpr. | 0.95% -1.34% | SMA200 | -14.76% ($93.52) | Avg Volume(3M) | 4.99M | Price | $79.72 |
| IPO | 2013/2/1 | Option/Short | Yes/Yes | Trades | 33174 | Volume | 4,118,156 | Change | 1.17% |
🐾 Zoetis (ZTS) is a global leader in the animal pharmaceuticals, vaccines, and diagnostics market, with a broad product portfolio spanning both companion animals and livestock. Since becoming an independent company from a global pharmaceutical company in 2013, it has maintained a top global position in the single category of animal healthcare.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
Next earnings report: November 5
4 days to go.
ZTS makes money exceptionally well
Of every $100 in sales, $37.65 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -3.1% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $996. Peers typically go for $1,453. Compared with its own 5-year average, it is 63% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -63.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 2.64% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 100.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #4 of 83 in the industry
Based on market cap of $33B.
FAQ
What kind of company is ZTS?
ZTS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ZTS?
The market cap of ZTS is approximately $32.9B, ranking 439 within its sector.
Does ZTS pay dividends?
ZTS has a dividend yield of approximately 2.64%, with an annual dividend of $2.11.
What is the P/E ratio of ZTS?
ZTS has a P/E ratio of approximately 13.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ZTS?
ZTS has recorded a 52-week high of $145.04 and a low of $68.77.
